LGM2605 is a synthetic version of the naturally occurring flaxseed lignan secoisolariciresinol diglucoside (SDG), with known anti‐inflammatory and antioxidant properties; however, its effects on gut microbial composition have not previously been evaluated. In the present study, we sought to determine how the 10‐day oral administration of LGM2605 alters the gut microbiota of mice. Eight‐week‐old female C57BL/6 mice were treated with either LGM2605 or saline, administered daily via oral gavage over a 10‐day treatment period. Upon termination of treatment, mouse cecums (n = 31) were collected, and cecal DNA was isolated. 16S rRNA genes were sequenced and analyzed in Mothur to identify changes in gut microbial composition induced by LGM2605 treatment (v. saline control). We then assessed community composition, performed indicator taxa analysis, and measured alpha and beta diversity. Overall, LGM2605 significantly altered the gut microbiota of mice; we reported alterations in 3 bacterial phyla and 22 genera as a result of treatment. The study here identifies for the first time significant alterations in the gut microbiota of mice following oral administration of LGM2605, in general shifting toward a more anti‐inflammatory composition. These findings lay the foundation for future investigations utilizing LGM2605 to control gut dysbiosis and, by extension, systemic inflammation.

中文翻译：

---

短期接触合成亚麻籽木脂素 LGM2605 会改变小鼠的肠道微生物群

LGM2605 是天然亚麻籽木脂素开环异落叶松树脂二葡糖苷 (SDG) 的合成版本，具有已知的抗炎和抗氧化特性；然而，此前尚未评估其对肠道微生物组成的影响。在本研究中，我们试图确定 10 天口服 LGM2605 如何改变小鼠的肠道微生物群。八周大的雌性 C57BL/6 小鼠用 LGM2605 或生理盐水治疗，在 10 天的治疗期内每天通过口服管饲给药。治疗结束后，小鼠盲肠 ( n = 31) 被收集，并分离盲肠 DNA。在 Mothur 中对 16S rRNA 基因进行测序和分析，以确定 LGM2605 处理（与盐水对照）诱导的肠道微生物组成的变化。然后我们评估了群落组成，进行了指标类群分析，并测量了 alpha 和 beta 多样性。总体而言，LGM2605 显着改变了小鼠的肠道微生物群；我们报告了治疗后 3 个细菌门和 22 个属的改变。该研究首次确定了口服 LGM2605 后小鼠肠道微生物群的显着变化，通常转向更具抗炎性的组合物。这些发现为未来利用 LGM2605 控制肠道菌群失调以及全身炎症的研究奠定了基础。